Search Within

Robin Beth Brenner

  1. "Body Imaging Service"
Formats
  1. Meeting Abstract (4)
  2. Journal Article (2)
Groups
  1. Body Imaging Service (6)
  2. Center for Pancreatic Cancer Research (6)
  3. Department of Medicine (6)
  4. Gastrointestinal Oncology Service (6)
  5. Radiology, Department of (6)
  6. Solid Tumor Oncology Division (6)

More Groups

People
  1. Eileen O'Reilly (6)
  2. Kenneth Yu (6)
  3. Kinh Gian Do (5)
  4. Alice Zervoudakis (4)
  5. David Kelsen (4)
  6. Maeve Lowery (4)

More People

Years
  1. 2020 (2)
  2. 2018 (3)
  3. 2016 (1)
Publications
  1. Journal of Clinical Oncology (4)
  2. Annals of Oncology (1)
  3. Cancer (1)
Publishers
  1. American Society of Clinical Oncology (4)
  2. Oxford University Press (1)
  3. Wiley Blackwell (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C) plus /- veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g)BRCA/ PALB2 mutation
    Meeting Abstract

    O'Reilly, E. M.; Lee, J. W.; Zalupski, M.; Capanu, M.; Park, J.; Golan, T.; Tahover, E.; Lowery, M. A.; Chou, J. F.; Sahai, V.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation
    Journal Article

    O'Reilly, E. M.; Lee, J. W.; Zalupski, M.; Capanu, M.; Park, J.; Golan, T.; Tahover, E.; Lowery, M. A.; Chou, J. F.; Sahai, V.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Pilot study of gemcitabine, nab-paclitaxel, PEGPH20, and rivaroxaban for advanced pancreatic adenocarcinoma: An interim analysis
    Meeting Abstract

    Yu, K. H.; Mantha, S.; Tjan, C.; Kaufmann, E. S.; Brenner, R.; Lowery, M. A.; Ku, G. Y.; Raj, N. P.; Shcherba, M.; Goldberg, Z.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A pilot study of gemcitabine, nab-paclitaxel, PEGPH20 (PAG) and rivaroxaban for advanced pancreatic adenocarcinoma: Interim safety and efficacy analysis
    Meeting Abstract

    Yu, K.; Mantha, S.; Tjan, C.; Kaufmann, E.; Brenner, R. B.; Lowery, M.; Ku, G.; Raj, N.; Shcherba, M.; Goldberg, Z.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma
    Journal Article

    O'Reilly, E. M.; Lee, J. W.; Lowery, M. A.; Capanu, M.; Stadler, Z. K.; Moore, M. J.; Dhani, N.; Kindler, H. L.; Estrella, H.; Maynard, H.; more...
    Cancer (2018)

    Fulltext@MSK | Save
  • Phase 1B trial of ADI-PEG 20 (A) plus nab-paclitaxel (nab-P) and gemcitabine (gem) in subjects with advanced pancreatic cancer (APC)
    Meeting Abstract

    Lowery, M. A.; Capanu, M.; Glassman, D. C.; Covington, C. M.; Gluskin, J.; Brenner, R.; Li, C. F.; Bomalaski, J. S.; Johnston, A.; Barba, A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save